AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27940181 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVE+ intervention (multilevel individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity)
Number of subjects: 720
Study 27940181 — intervention group
Group type: EXPERIMENTAL
Intervention: STAND+ intervention (MOVE+ intervention with sit-stand workstations)
Number of subjects: 720
Study 26072382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive coping and relaxation intervention (CCRI)
Number of subjects: 166
Study 26072382 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 166
Study 23046147 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25μg
Number of subjects: 116
Study 23046147 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 50μg
Number of subjects: 116
Study 23046147 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 100μg
Number of subjects: 116
Study 23046147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 16596358 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 (0.5 U/kg, split into 0.25 U/kg at 08.30 h and 0.25 U/kg at 20.30 h)
Number of subjects: 12
Study 16596358 — intervention group
Group type: COMPARATOR
Intervention: IGlarg (0.5 U/kg at 08.30 h)
Number of subjects: 12
Study 14687254 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based cardiac care suggestions
Number of subjects: 706
Study 10472344 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine as a bolus injection (200 mg/m2 dissolved in 10 ml sodium chloride 0.9%)
Number of subjects: 42
Study 10472344 — intervention group
Group type: COMPARATOR
Intervention: Amifostine as a bolus injection
Number of subjects: 42
Study 8709324 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg urapidil for 4 weeks (group 2)
Number of subjects: 136
Study 8709324 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg urapidil for 2 weeks followed by 60 mg for 2 weeks (group 3)
Number of subjects: 136
Study 8709324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 136
Study 1876628 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 micrograms/kg, single i.v. dose)
Number of subjects: 18
Study 1876628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6283753 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg penbutolol (pure S‐form)
Number of subjects: 9
Study 6283753 — intervention group
Group type: COMPARATOR
Intervention: 40 mg isopenbutolol (pure R‐form)
Number of subjects: 9
Study 31738579 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected suicide attempt by a motor vehicle driver crashing into their vehicle
Number of subjects: 863
Study 31738579 — intervention group
Group type: EXPERIMENTAL
Intervention: Resulting crash from a suspected suicide attempt
Number of subjects: 863
Study 31738579 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal knowledge of another driver experiencing a crash caused by a suicidal driver
Number of subjects: 863
Study 31738579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of suicide attempts by crashing into their vehicle
Number of subjects: 863
Study 31738579 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety about the possibility of a suicide attempt
Number of subjects: 863
Study 31738579 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges of avoiding a crash caused by a suicidal driver
Number of subjects: 863
Study 28762437 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intensive lifestyle intervention (ILI)
Number of subjects: 140
Study 28762437 — intervention group
Group type: COMPARATOR
Intervention: Education-only active comparator (AC)
Number of subjects: 140
Study 25079477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg alginate plus simethicone
Number of subjects: 75
Study 25079477 — intervention group
Group type: COMPARATOR
Intervention: Thickened formula
Number of subjects: 75
Study 25079477 — intervention group
Group type: COMPARATOR
Intervention: Reassurance with lifestyle changes
Number of subjects: 75
Study 22726703 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigating drains (red rubber catheters)
Number of subjects: 46
Study 22726703 — intervention group
Group type: COMPARATOR
Intervention: Nonirrigating drains (Penrose drains)
Number of subjects: 46
Study 21700623 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oseltamivir in morbidly obese patients
Number of subjects: 2
Study 21700623 — intervention group
Group type: COMPARATOR
Intervention: Single-dose oseltamivir in control (non-obese) subjects
Number of subjects: 2
Study 21700623 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oseltamivir carboxylate in morbidly obese patients
Number of subjects: 2
Study 21700623 — intervention group
Group type: COMPARATOR
Intervention: Single-dose oseltamivir carboxylate in control (non-obese) subjects
Number of subjects: 2
Study 19363607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucillamine (Buc)
Number of subjects: 49
Study 19363607 — intervention group
Group type: COMPARATOR
Intervention: Salazosulfapyridine (SASP)
Number of subjects: 49
Study 16739183 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary therapist model (PTM)
Number of subjects: 111
Study 16739183 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment model (TTM)
Number of subjects: 111
Study 15520323 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg PO
Number of subjects: 20
Study 15520323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11397030 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforate Invagination (PIN) stripping
Number of subjects: 80
Study 11397030 — intervention group
Group type: COMPARATOR
Intervention: Conventional stripping
Number of subjects: 80
Study 9237091 — intervention group
Group type: EXPERIMENTAL
Intervention: supervised home‐based exercise (higher or lower intensity)
Number of subjects: 269
Study 9237091 — intervention group
Group type: COMPARATOR
Intervention: group‐based exercise program
Number of subjects: 269
Study 9237091 — intervention group
Group type: EXPERIMENTAL
Intervention: short-term adherence predictors
Number of subjects: 269
Study 8098243 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg once-daily nebivolol
Number of subjects: 25
Study 8098243 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg once-daily nebivolol
Number of subjects: 25
Study 8098243 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg once-daily atenolol
Number of subjects: 25
Study 8098243 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg once-daily atenolol
Number of subjects: 25
Study 8098243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3632148 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal with prebound aspirin
Number of subjects: 8
Study 29710042 — intervention group
Group type: EXPERIMENTAL
Intervention: 1975 Japanese diet (JD)
Number of subjects: 32
Study 26704028 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 14784
Study 26704028 — intervention group
Group type: COMPARATOR
Intervention: Heparin + GPI
Number of subjects: 14784
Study 26231856 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 390
Study 26231856 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 390
Study 23560584 — intervention group
Group type: EXPERIMENTAL
Intervention: Petrolatum jelly
Number of subjects: 213
Study 23560584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no petrolatum jelly)
Number of subjects: 213
Study 21038951 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning (repeated pairing of the cue with consumption of a highly disliked liquid, Polysorbate 20)
Number of subjects: 0
Study 21038951 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning
Number of subjects: 0
Study 21038951 — intervention group
Group type: COMPARATOR
Intervention: Extinction (repeated presentation of the cue without chocolate consumption)
Number of subjects: 0
Study 18164894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavioral intervention
Number of subjects: 636
Study 18164894 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 636
Study 16731999 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 1501
Study 16731999 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 1501
Study 12714026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice daily)
Number of subjects: 629
Study 12714026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 629
Study 11091497 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+‐enriched autologous stem cell grafts
Number of subjects: 27
Study 11091497 — intervention group
Group type: COMPARATOR
Intervention: Unmanipulated autologous stem cell grafts
Number of subjects: 27
Study 8925996 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately differentiated adenocarcinomas (G2)
Number of subjects: 50
Study 8925996 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly differentiated adenocarcinomas
Number of subjects: 50
Study 8925996 — intervention group
Group type: COMPARATOR
Intervention: Control group (proliferative endometrium)
Number of subjects: 50
Study 8925996 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study group (endometrial carcinoma)
Number of subjects: 50
Study 8925996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcoma uteri patients
Number of subjects: 50
Study 1360699 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat fibre (16 g day-1)
Number of subjects: 10
Study 1360699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula (16 g day-1)
Number of subjects: 10
Study 1360699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during wash-out period)
Number of subjects: 10
Study 6145726 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (2 mg)
Number of subjects: 48
Study 6145726 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15.8 mg)
Number of subjects: 48
Study 6145726 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 48
Study 29402522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/rosuvastatin 20 mg
Number of subjects: 396
Study 29402522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/rosuvastatin 10 mg
Number of subjects: 396
Study 29402522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/rosuvastatin 5 mg
Number of subjects: 396
Study 29402522 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 396
Study 29402522 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 396
Study 29402522 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 5 mg
Number of subjects: 396
Study 26965765 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (75 g per day)
Number of subjects: 10
Study 26965765 — intervention group
Group type: COMPARATOR
Intervention: Standard carbohydrate counting
Number of subjects: 10
Study 24899759 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment of Insomnia (BBTI)
Number of subjects: 79
Study 24899759 — intervention group
Group type: COMPARATOR
Intervention: Information-only Control (IC)
Number of subjects: 79
Study 22190001 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (gel)
Number of subjects: 38
Study 20122739 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal/grid photocoagulation
Number of subjects: 330
Study 17441219 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and 1′-hydroxymidazolam determination using liquid chromatography-tandem mass spectrometry
Number of subjects: 0
Study 16170182 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine 250 mg/m2 and cisplatin 30 mg/m2 combined with interferon‐alfa‐2b 10 x 10(6) U/m2 (arm A)
Number of subjects: 363
Study 16170182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine 250 mg/m2 and cisplatin 30 mg/m2 combined with interferon‐alfa‐2b 10 x 10(6) U/m2 and IL-2 (arm B)
Number of subjects: 363
Study 16170182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine, cisplatin, interferon‐alfa‐2b, and IL-2 (arm B)
Number of subjects: 363
Study 16170182 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine, cisplatin, and interferon‐alfa‐2b (arm A)
Number of subjects: 363
Study 11994348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) injections
Number of subjects: 30
Study 11994348 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) and P (RT + P)
Number of subjects: 30
Study 11994348 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injections of testosterone (100 mg/wk)
Number of subjects: 30
Study 11994348 — intervention group
Group type: EXPERIMENTAL
Intervention: RT and T (RT + T)
Number of subjects: 30
Study 19667501 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 19667501 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (e.g., paroxetine, citalopram)
Number of subjects: 0
Study 7486177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 21
Study 7486177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 60% N2O
Number of subjects: 21
Study 7486177 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 21
Study 2107135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin 1.5 micrograms/kg/h
Number of subjects: 8
Study 2107135 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% or 0.1 M HCl (control)
Number of subjects: 8
Study 2107135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion
Number of subjects: 8
Study 84260 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of vitamin C given daily for 28 days
Number of subjects: 0
Study 84260 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 29900553 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 weeks
Number of subjects: 60
Study 29900553 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks
Number of subjects: 60
Study 27346063 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24783926 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-element music therapy
Number of subjects: 50
Study 24783926 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 50
Study 23128580 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) training for primary care physicians
Number of subjects: 2965
Study 19933120 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, child-centred and family-based program
Number of subjects: 67
Study 19933120 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study 18482026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0
Study 16885792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 102
Study 16885792 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 102
Study 11470150 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)‐10
Number of subjects: 0
Study 9604591 — intervention group
Group type: EXPERIMENTAL
Intervention: HbS (study group)
Number of subjects: 310
Study 9604591 — intervention group
Group type: COMPARATOR
Intervention: HbA (control group)
Number of subjects: 310
Study 8002850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol reduction treatment
Number of subjects: 50000
Study 2544249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactinomycin (Actinomycin D) and Vincristine for 10 weeks
Number of subjects: 1439
Study 2544249 — intervention group
Group type: COMPARATOR
Intervention: Dactinomycin (Actinomycin D) and Vincristine for 6 months
Number of subjects: 1439
Study 2544249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactinomycin (Actinomycin D) + Vincristine +/− Adriamycin for 15 months
Number of subjects: 1439
Study 2544249 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy and Dactinomycin (Actinomycin D) + Vincristine + Adriamycin +/− Cyclophosphamide
Number of subjects: 1439
Study 1586788 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast shells
Number of subjects: 96
Study 1586788 — intervention group
Group type: COMPARATOR
Intervention: No shells
Number of subjects: 96
Study 1586788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoffman's exercises
Number of subjects: 96
Study 1586788 — intervention group
Group type: COMPARATOR
Intervention: No exercises
Number of subjects: 96
Study 1586788 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended shells
Number of subjects: 96
Study 1586788 — intervention group
Group type: COMPARATOR
Intervention: Not recommended shells
Number of subjects: 96
Study 1586788 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises
Number of subjects: 96
Study 580761 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (oral dose, specific dosage not mentioned)
Number of subjects: 0
Study 580761 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing oral dose of rifampicin
Number of subjects: 0
Study 580761 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (oral dosage forms of the same nominal strength)
Number of subjects: 0
Study 31981713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifapentine with moxifloxacin for four months
Number of subjects: 2500
Study 31981713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifapentine without moxifloxacin for four months
Number of subjects: 2500
Study 31981713 — intervention group
Group type: COMPARATOR
Intervention: Conventional six-month treatment regimen
Number of subjects: 2500
Study 31042154 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile prenatal care app
Number of subjects: 88
Study 31042154 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 88
Study 28245151 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-solid nodules
Number of subjects: 19
Study 26181019 — intervention group
Group type: EXPERIMENTAL
Intervention: More optimistic message video
Number of subjects: 100
Study 26181019 — intervention group
Group type: COMPARATOR
Intervention: Less optimistic message video
Number of subjects: 100
Study 26181019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence effect of video order
Number of subjects: 100
Study 26181019 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in medical profession after viewing messages
Number of subjects: 100
Study 23240909 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of AS03‐adjuvanted A/California/7/2009 (H1N1) vaccine
Number of subjects: 42
Study 23240909 — intervention group
Group type: COMPARATOR
Intervention: Two doses of AS03‐adjuvanted A/California/7/2009 (H1N1) vaccine
Number of subjects: 42
Study 20860765 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of a tongue protector (group B)
Number of subjects: 65
Study 20860765 — intervention group
Group type: COMPARATOR
Intervention: Informed therapy (group A)
Number of subjects: 65
Study 19531054 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide/metformin FDC BID
Number of subjects: 561
Study 19531054 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide/metformin FDC TID
Number of subjects: 561
Study 17327813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.1 mg/kg)
Number of subjects: 34
Study 17327813 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (titrated doses)
Number of subjects: 34
Study 15450558 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 82
Study 15450558 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 82
Study 12043873 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine pellets (Racellet pellets)
Number of subjects: 0
Study 12043873 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ferric sulfate (Viscostat)
Number of subjects: 0
Study 9718615 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential currents (IFCs)
Number of subjects: 0
Study 9718615 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models
Number of subjects: 0
Study 7529155 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing whole blood samples or blocking with mouse immunoglobulin
Number of subjects: 0
Study 7529155 — intervention group
Group type: COMPARATOR
Intervention: Plasma, serum, or immunoglobulin preparations from donors
Number of subjects: 0
Study 2626955 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 25
Study 2626955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 823405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone
Number of subjects: 0
Study 823405 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31397726 — intervention group
Group type: EXPERIMENTAL
Intervention: ChildCARE intervention (caregiver intervention with five 2-hour sessions)
Number of subjects: 790
Study 31397726 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 790
Study 27284868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored ergonomics advice according to the stage of change (SOC) approach
Number of subjects: 0
Study 27284868 — intervention group
Group type: COMPARATOR
Intervention: Standard ergonomics advice
Number of subjects: 0
Study 25465291 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA) for 20 min with 3Back training
Number of subjects: 22
Study 25465291 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with 3Back training
Number of subjects: 22
Study 25465291 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA) for 20 min with 1Back training
Number of subjects: 22
Study 25465291 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with 1Back training
Number of subjects: 22